


Supplement Figure 1




Supplement Figure 1: Patient flow chart

Among total patient population, 274 were excluded because they did not meet the inclusion criteria: 109 patients had history of previous PCI, 18 patients had history of CABG, 122 patients lost to follow-up CAG, 20 patients loss to follow-up blood test. We finally identified 283 consecutive patients with de novo ACS who were eligible for enrollment. Patients were grouped according to treatment before the guideline update (Group 1, n=182) and after the guideline update (Group 2, n=101) according to the onset of index ACS. ACS, acute coronary syndrome; PCI, percutaneous coronary intervention; CABG, coronary artery bypass surgery; CAG, coronary angiography; SM, smoker; ACEi, angiotensin-converting enzyme Inhibitor; ARB, angiotensin II receptor blocker

Supplement Figure 2

Achievement rates of new guideline targets



* Atorvastatin 20mg, Rosuvastatin 10mg, Pitavastatin 4mg

Supplement Figure 2: Achievement rates of new guideline target goal under 70 mg/dl

High-intensity statins were defined as atorvastatin at 20 mg/day, rosuvastatin at 10 mg/day, and pitavastatin at 4 mg/day.